What do systematic reviews say?

Topical antibiotics with steroids vs topical antibiotics

The review found no eligible studies for this question.

• Topical antibiotics with steroids for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Topical antibiotics with steroids for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical antibiotics with steroids vs placebo/no treatment

The review found no eligible studies for this question.

• Topical antibiotics with steroids for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Anabolic steroids vs no intervention

The review found no eligible studies for this question.

• Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Glucocorticosteroids vs no intervention

The review found no eligible studies for this question.

• Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Glucocorticosteroids vs no intervention

The review found no eligible studies for this question.

• Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intranasal corticosteroids vs placebo

• Intranasal corticosteroids for non‐allergic rhinitis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Glucocorticosteroids for infants with biliary atresia following Kasai portoenterostomy 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 38 participants
  Very low

Intervention not reported

The intervention showed no clear difference in health‐related quality of life: up to 3 months ( (low certainty).

• Glucocorticosteroids for people with alcoholic hepatitis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 377 participants
  Low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 784 participants
  High

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 265 participants
  Moderate

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 105 participants
  Low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 766 participants
  Moderate

ICS dose reduction vs no change

• Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 554 participants
  Very low

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 105 participants
  Low